Personalized neoantigen-specific adoptive T cell therapy for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
Valentina Ferrari1, Alison Tarke1, Hannah Fields1, Luca Ferrari1, Trevor Conley1, Franco Ferrari1, Jie-Hua Zhou2, Dimitrios Tzachanis2, Tiffany Tanaka3, Asad Bashey4, Rafael Bejar3, Thomas Lane1, Edward D. Ball2, Antonella Vitiello1*
1PersImmune, San Diego, CA, 2Blood and Marrow Transplant Division and 3Hematology and Oncology Division, UCSD, San Diego, CA; 4Northside Blood and Marrow Transplant Division, Atlanta, GA
The 5-year survival rate for patients with AML is ~25% and the 2-year survival rate for patients with high risk MDS who fail standard therapy is ~15%. At present, the only curative therapy for most high-risk AML and MDS patients is allogeneic hematopoietic stem cell transplant (allo-HSCT). We have developed a personalized adoptive T cell therapy predicated on the concept that cancer is caused by somatic mutations that generate potentially novel immunogenic proteins (neoantigens).
Our process comprises (i) whole-exome and transcriptome sequencing of AML/MDS patient neoplastic blasts and exome and transcriptome sequencing of patient normal hematopoietic cells to identify non-synonymous tumor-unique DNA mutations; (ii) in silico screening of peptides spanning the resulting mutation to identify potentially immunogenic MHC-binding peptides; (iii) in vitro immunogenicity screening of candidate peptides against T cells from the AML allo-HSCT donor or the MDS patient; and (iv) selection of immunogenic peptides and large-scale generation of T cell lines with the desired neoantigen specificity and cytolytic activity for infusion into patients.
Here, we present data demonstrating the entire process of T cell generation, starting with identification of somatic mutations from AML/MDS patients through to in vitro generation of autologous and HLA-matched allogeneic cytotoxic T cell lines specific for neoantigen-expressing AML blasts.
Two phase I clinical trials to assess the safety and tolerability of this personalized T cell therapy in AML and MDS patients are planned for 2017.
Funded by Raffaella and John Belanich.
You must be logged in and own this product in order to post comments.